◎ Sugi Atlas

Atlas / Drug / Sorafenib

Sorafenib

drug
On this page

Also known as SID50112741SID124893321baxSID103904444SID124893323SorafinibNexavarSorafenibSorafenibÊSorafenibÂSorafenib Tosylate

Summary

Sorafenib (CHEMBL1336) is an approved small-molecule antineoplastic agent (ATC L01EX02) targeting PDGFRB, KIT, and FLT3; indicated across 84 conditions including neoplasm and hepatocellular carcinoma; with CIViC clinical evidence for 73 variant-indication associations (e.g. FLT3 ITD in acute myeloid leukemia).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EX02
  • Targets: 13 (PDGFRB, KIT, FLT3…)
  • Indications: 84 conditions
  • Clinical trials: 568
  • Precision-oncology evidence (CIViC): 73 variant–indication associations
  • Chemistry: 464.8 Da · C21H16ClF3N4O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1336
NameSorafenib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID216239
ChEBICHEBI:50924
ATCL01EX02
Molecular formulaC21H16ClF3N4O3
Molecular weight464.8
InChIKeyMLDQJTXFUGDVEO-UHFFFAOYSA-N

SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

IUPAC name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide

ChEBI definition: A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, tyrosine kinase inhibitor, angiogenesis inhibitor, anticoronaviral agent, ferroptosis inducer.

Also known as: Sorafenib, sorafenib, SID50112741, SID124893321, bax, SID103904444, SORAFENIB, SID124893323, Sorafinib, Nexavar; Sorafenib, SorafenibÊ, SorafenibÂ

Parent form; salt/anhydrous children: CHEMBL1200485, CHEMBL1760433, CHEMBL4297490

Patent coverage: 22,883 distinct patent families (86,060 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 83,779 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDGFRBplatelet derived growth factor receptor betaInhibition7.242.3%P09619
KITKIT proto-oncogene, receptor tyrosine kinaseInhibition7.170.5%P10721
FLT3fms related receptor tyrosine kinase 3Inhibition7.240.9%P36888
FGFR1fibroblast growth factor receptor 1Inhibition6.2411.5%P11362
KDRkinase insert domain receptorInhibition7.051.1%P35968
FLT4fms related receptor tyrosine kinase 4Inhibition7.70.2%P35916
DDR2discoidin domain receptor tyrosine kinase 2Inhibition80%Q16832
BRAFB-Raf proto-oncogene, serine/threonine kinaseInhibition7.668.6%P15056
CDK19cyclin dependent kinase 19Inhibition6.990.1%Q9BWU1
CDK8cyclin dependent kinase 8Inhibition76.5%P49336
RAF1Raf-1 proto-oncogene, serine/threonine kinaseInhibition8.22P04049
RETret proto-oncogeneInhibition7.90.4%P07949
TNNI3KTNNI3 interacting kinaseBinding6.550%Q59H18

Broader ChEMBL bioactivity targets: 161 (assay-derived). Sample: Homeodomain-interacting protein kinase 4, Serine/threonine-protein kinase TAO2, Cyclin-dependent kinase-like 3, Serine/threonine-protein kinase A-Raf, Nuclear receptor ROR-gamma, Receptor-interacting serine/threonine-protein kinase 3, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor.

Bioactivity

ChEMBL activities: 902 potent at pChembl ≥ 5 of 915 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
KDR10.68Ki0.02nMCHEMBL_ACT_6324306
KDR10.22IC500.06nMCHEMBL_ACT_24687339
KDR9.92Ki0.12nMCHEMBL_ACT_6324310
KDR9.8IC500.16nMCHEMBL_ACT_6324286
EPHB49.7IC500.2nMCHEMBL_ACT_17955698
EPHB49.66IC500.22nMCHEMBL_ACT_18947881
EPHB49.66IC500.22nMCHEMBL_ACT_19364908
PDGFRB9.59IC500.26nMCHEMBL_ACT_28855802
KDR9.47IC500.34nMCHEMBL_ACT_28855805
TEK9.41IC500.39nMCHEMBL_ACT_18947864
TEK9.41IC500.39nMCHEMBL_ACT_19364887
KDR9.35IC500.45nMCHEMBL_ACT_17955648
KDR9.32IC500.48nMCHEMBL_ACT_15625880
KDR9.32IC500.48nMCHEMBL_ACT_15765248
KDR9.26IC500.55nMCHEMBL_ACT_26150949
ERBB29.25IC500.56nMCHEMBL_ACT_28855799
TEK9.08IC500.83nMCHEMBL_ACT_17955673
KDR9.07IC500.85nMCHEMBL_ACT_15154943
KDR9.07IC500.85nMCHEMBL_ACT_18328417
BRAF9IC501nMCHEMBL_ACT_2397024
RAF19IC501nMCHEMBL_ACT_2397034
BRAF9IC501nMCHEMBL_ACT_5199776
KDR8.97IC501.06nMCHEMBL_ACT_13868196
KDR8.97IC501.06nMCHEMBL_ACT_14544388
KDR8.92IC501.2nMCHEMBL_ACT_16395735
KDR8.9IC501.27nMCHEMBL_ACT_18355977
FLT38.89IC501.3nMCHEMBL_ACT_19043595
KDR8.85IC501.42nMCHEMBL_ACT_16435131
DDR18.82Kd1.5nMCHEMBL_ACT_15240090
DDR18.82Kd1.5nMCHEMBL_ACT_2897532

Target pathways

Aggregated over 13 target gene(s): PDGFRB, KIT, FLT3, FGFR1, KDR, FLT4, DDR2, BRAF, CDK19, CDK8, RAF1, RET, TNNI3K.

Top Reactome pathways

157 total, by targets touching each:

PathwayTargetsGenes
RAF/MAP kinase cascade6BRAF, FGFR1, FLT3, KIT, PDGFRB, RET
PIP3 activates AKT signaling4FGFR1, FLT3, KIT, PDGFRB
Disease4BRAF, CDK19, CDK8, KIT
Constitutive Signaling by Aberrant PI3K in Cancer4FGFR1, FLT3, KIT, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling4FGFR1, FLT3, KIT, PDGFRB
Developmental Biology3CDK19, CDK8, KIT
Signal Transduction3BRAF, CDK8, KIT
Diseases of signal transduction by growth factor receptors and second messengers3BRAF, CDK8, KIT
PI3K Cascade2FGFR1, FLT3
Metabolism2CDK19, CDK8
VEGF binds to VEGFR leading to receptor dimerization2FLT4, KDR
PPARA activates gene expression2CDK19, CDK8
Generic Transcription Pathway2CDK8, KIT
Transcriptional regulation of white adipocyte differentiation2CDK19, CDK8
Regulation of lipid metabolism by PPARalpha2CDK19, CDK8
Metabolism of lipids2CDK19, CDK8
Negative regulation of FGFR1 signaling2BRAF, FGFR1
Infectious disease2CDK19, CDK8
RAF activation2BRAF, RAF1
MAP2K and MAPK activation2BRAF, RAF1
Negative feedback regulation of MAPK pathway2BRAF, RAF1
Negative regulation of MAPK pathway2BRAF, RAF1
MAPK family signaling cascades2BRAF, KIT
MAPK1/MAPK3 signaling2BRAF, KIT
Signaling by moderate kinase activity BRAF mutants2BRAF, RAF1
Signaling by high-kinase activity BRAF mutants2BRAF, RAF1
Signaling by BRAF and RAF1 fusions2BRAF, RAF1
Paradoxical activation of RAF signaling by kinase inactive BRAF2BRAF, RAF1
RNA Polymerase II Transcription2CDK8, KIT
Gene expression (Transcription)2CDK8, KIT

Dominant GO biological processes

GO termTargets
protein phosphorylation13
cell surface receptor protein tyrosine kinase signaling pathway7
positive regulation of cell population proliferation7
protein autophosphorylation7
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction7
positive regulation of MAPK cascade7
signal transduction6
peptidyl-tyrosine phosphorylation6
cell migration6
positive regulation of cell migration5
positive regulation of ERK1 and ERK2 cascade5
negative regulation of apoptotic process5
angiogenesis4
MAPK cascade4
positive regulation of MAP kinase activity3

Indications & clinical

Indications

84 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm3MONDO:0005070EFO:0000616
hepatocellular carcinoma3MONDO:0007256EFO:0000182
renal cell carcinoma3MONDO:0005086EFO:0000681
kidney neoplasm3MONDO:0021163EFO:0003865
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
thyroid gland carcinoma3MONDO:0015075EFO:0002892
melanoma3MONDO:0005105EFO:0000756
carcinoma3MONDO:0004993EFO:0000313
thyroid tumor3MONDO:0015074EFO:0003841
thyroid gland papillary carcinoma3MONDO:0005075EFO:0000641
hepatoblastoma3MONDO:0018666EFO:1000292
kidney cancer3MONDO:0002367MONDO:0002367
breast neoplasm3MONDO:0021100MONDO:0007254
acute myeloid leukemia2MONDO:0018874EFO:0000222
sarcoma2MONDO:0005089EFO:0000691
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
leukemia2MONDO:0005059EFO:0000565
portal hypertension2MONDO:0005080EFO:0000666
keloid2MONDO:0005348EFO:0004212
osteosarcoma2MONDO:0009807EFO:0000637
small cell lung carcinoma2MONDO:0008433EFO:0000702
testicular cancer2MONDO:0005447EFO:0005088
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
myelodysplastic syndrome2MONDO:0018881EFO:0000198
adenocarcinoma2MONDO:0004970EFO:0000228
chronic myeloid leukemia2MONDO:0011996EFO:0000339
glioblastoma2MONDO:0018177EFO:0000519
mesothelioma2MONDO:0005065EFO:0000588
neuroblastoma2MONDO:0005072EFO:0000621
prostate adenocarcinoma2MONDO:0005082EFO:0000673
rhabdomyosarcoma2MONDO:0005212EFO:0002918
kidney disorder2MONDO:0005240EFO:0003086
pancreatic neoplasm2MONDO:0021040EFO:0003860
ovarian neoplasm2MONDO:0021068EFO:0003893
colorectal neoplasm2MONDO:0005335EFO:0004142
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
gliosarcoma2MONDO:0016681EFO:1001465
soft tissue sarcoma2MONDO:0018078EFO:1001968
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
gastric neoplasm2MONDO:0021085MONDO:0001056
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
bile duct carcinoma2MONDO:0005496EFO:0005540
uveal melanoma2MONDO:0006486EFO:1000616
salivary gland cancer2MONDO:0004669MONDO:0004669
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
gallbladder neoplasm2MONDO:0021253MONDO:0005411
Hermansky-Pudlak syndrome2MONDO:0019312MONDO:0019312
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
lymphoma1MONDO:0005062EFO:0000574
squamous cell carcinoma1MONDO:0005096EFO:0000707
pulmonary arterial hypertension1MONDO:0015924EFO:0001361
acute promyelocytic leukemia1MONDO:0012883EFO:0000224
cervical carcinoma1MONDO:0005131EFO:0001061
plasma cell myeloma1MONDO:0009693EFO:0001378
liver disorder1MONDO:0005154EFO:0001421
anaplastic astrocytoma1MONDO:0016684EFO:0002499
anaplastic oligodendroglioma1MONDO:0016696EFO:0002501
rectal cancer1MONDO:0006519EFO:1000657
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
small cell carcinoma1MONDO:0000402EFO:0008524
thrombotic disease1MONDO:0000831MONDO:0000831
Kaposi’s sarcoma1MONDO:0005055EFO:0000558
brain neoplasm1MONDO:0021211EFO:0003833
plasma cell neoplasm1MONDO:0004959EFO:0000200
cholangiocarcinoma1MONDO:0019087EFO:0005221
myeloid leukemia1MONDO:0004643MONDO:0004643

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 568.

Phase distribution

PhaseTrials
PHASE2247
PHASE1130
PHASE366
PHASE1/PHASE265
Not specified37
PHASE2/PHASE313
PHASE49
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01409499PHASE4COMPLETEDPalliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01849588PHASE4TERMINATEDHCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
NCT02504983PHASE4UNKNOWNClinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
NCT02733809PHASE4UNKNOWNMechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
NCT02961998PHASE4COMPLETEDPreventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
NCT03178656PHASE4UNKNOWNA Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
NCT03518502PHASE4UNKNOWNSorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
NCT04127396PHASE4UNKNOWNLenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
NCT05113290PHASE4UNKNOWNEffect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
NCT03017326PHASE3ACTIVE_NOT_RECRUITINGPaediatric Hepatic International Tumour Trial
NCT03298451PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03533582PHASE3ACTIVE_NOT_RECRUITINGCisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03755791PHASE3ACTIVE_NOT_RECRUITINGStudy of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT04039607PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT04344158PHASE3ACTIVE_NOT_RECRUITINGA Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04770896PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT06972641PHASE2/PHASE3RECRUITINGMolecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07264010PHASE2/PHASE3NOT_YET_RECRUITINGSorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
NCT07463651PHASE3RECRUITINGMRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT00110019PHASE3COMPLETEDCarboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00326898PHASE3COMPLETEDSunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT00474786PHASE3COMPLETEDTemsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
NCT00478114PHASE3COMPLETEDEfficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00492258PHASE3COMPLETEDSorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
NCT00541021PHASE3UNKNOWNGemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00558636PHASE3TERMINATEDA Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00606866PHASE3COMPLETEDMRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
NCT00678392PHASE3COMPLETEDAxitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
NCT00699374PHASE3TERMINATEDStudy Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
NCT00732914PHASE3COMPLETEDSequential Study to Treat Renal Cell Carcinoma
NCT00858871PHASE3COMPLETEDFirst Line Hepato Cellular Carcinoma (HCC)
NCT00920816PHASE3COMPLETEDAxitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
NCT01004978PHASE3COMPLETEDChemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01009593PHASE3TERMINATEDEfficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01015833PHASE3COMPLETEDSorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT01030783PHASE3COMPLETEDA Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01075555PHASE3COMPLETEDSorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
NCT01076010PHASE3COMPLETEDAn Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT01135056PHASE3UNKNOWNStudy to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
NCT01214343PHASE3UNKNOWNComparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC

Clinical evidence (CIViC)

Variant × indication × effect (73 predictive associations from 80 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
FLT3 ITDAcute Myeloid LeukemiaSensitivity/ResponseSorafenibCIViC BEID1040 +2
FLT3 ITDAcute Myeloid LeukemiaSensitivity/ResponseSorafenib + Hematopoietic Cell TransplantationCIViC BEID9069 +1
CCND1 AmplificationSkin MelanomaSensitivity/ResponseSorafenib + Carboplatin + PaclitaxelCIViC BEID1495
FLT3 D835 & I836Acute Myeloid LeukemiaSensitivity/ResponseLestaurtinib + Quizartinib + Sorafenib + FLT3/ABL/Aurora Kinase Inhibitor KW-2449CIViC BEID8925
KIT Exon 11 Mutation OR KIT Exon 9 Mutation OR PDGFRA Exon 18 MutationGastrointestinal Stromal TumorSensitivity/ResponseSorafenibCIViC BEID11327
KRAS AmplificationSkin MelanomaSensitivity/ResponseSorafenib + Docetaxel + CarboplatinCIViC BEID1497
KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12PSolid Tumors, AdvancedSensitivity/ResponseSorafenibCIViC BEID12700
KRAS MutationHepatocellular CarcinomaSensitivity/ResponseSorafenib + RefametinibCIViC BEID1642
RAF1 AmplificationSkin MelanomaSensitivity/ResponsePaclitaxel + Sorafenib + CarboplatinCIViC BEID1496
RET M918TMedullary Thyroid CarcinomaSensitivity/ResponseSorafenibCIViC BEID1365
FLT3 D835Acute Myeloid LeukemiaResistanceQuizartinib + SorafenibCIViC BEID1038
FLT3 D835Acute Myeloid LeukemiaResistanceSorafenibCIViC BEID1039
FLT3 TKD MUTATIONAcute Myeloid LeukemiaResistanceSorafenibCIViC BEID248
HMOX1 EXPRESSIONRenal Cell CarcinomaResistanceSorafenib + SunitinibCIViC BEID829
PROM1 EXPRESSIONHepatocellular CarcinomaResistanceSorafenibCIViC BEID926
ARAF S214CLung Non-small Cell CarcinomaSensitivity/ResponseSorafenibCIViC CEID17 +1
FLT3 D835YAcute Myeloid LeukemiaSensitivity/ResponseSorafenibCIViC CEID12625 +1
KIAA1549::BRAF FusionSpindle Cell SarcomaSensitivity/ResponseSorafenib + Bevacizumab + TemsirolimusCIViC CEID1664 +1
AGK::BRAF FusionMelanomaSensitivity/ResponseSorafenibCIViC CEID723
BRAF G469RLung Non-small Cell CarcinomaSensitivity/ResponseSorafenibCIViC CEID1938
BRAF G469VLung Non-small Cell CarcinomaSensitivity/ResponseSorafenibCIViC CEID1939
FGF3 AmplificationHepatocellular CarcinomaSensitivity/ResponseSorafenibCIViC CEID1966
FLT3 AmplificationColorectal CancerSensitivity/ResponseSorafenibCIViC CEID7103
KIT D820EThymic CarcinomaSensitivity/ResponseSorafenibCIViC CEID7356
KIT P577_D579DELThymic CarcinomaSensitivity/ResponseSorafenibCIViC CEID7360
ZHX2 OverexpressionPapillary Renal Cell CarcinomaSensitivity/ResponseSorafenibCIViC CEID9114
FLT3 D835HAcute Myeloid LeukemiaResistanceSorafenibCIViC CEID1556
FLT3 ITD AND FLT3 D835YAcute Myeloid LeukemiaResistanceSorafenibCIViC CEID247
BRAF V600EMelanomaSensitivity/ResponseSorafenibCIViC DEID2122 +1
ARID1A LossLiver CancerSensitivity/ResponseSorafenibCIViC DEID7328

+43 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 40 clinical and 80 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

284 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AfatinibChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
CrizotinibChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
PAZOPANIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
FORETINIBChEMBLPhase 2BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
SelumetinibPubChemApprovedBRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
GEFITINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, RAF1, RET, TNNI3K
DORAMAPIMODChEMBLPhase 2BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET
RAF-265ChEMBLPhase 2BRAF, CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
ERLOTINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, DDR2, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
FEDRATINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
R-406ChEMBLPhase 2BRAF, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
AXITINIBChEMBL + PubChemPhase 4 (approved)CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
PONATINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, CDK8, DDR2, FGFR1, FLT3, KDR, KIT, PDGFRB, RET
QUIZARTINIBChEMBL + PubChemPhase 4 (approved)CDK19, CDK8, DDR2, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
REGORAFENIBChEMBL + PubChemPhase 4 (approved)BRAF, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET
SUNITINIBChEMBL + PubChemPhase 4 (approved)CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
VANDETANIBChEMBL + PubChemPhase 4 (approved)CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
DASATINIBChEMBLPhase 4 (approved)BRAF, DDR2, FGFR1, FLT3, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
LESTAURTINIBChEMBLPhase 3CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
LINIFANIBChEMBLPhase 3CDK19, CDK8, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
MOTESANIBChEMBLPhase 3BRAF, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET, TNNI3K
IMATINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, DDR2, FLT3, KDR, KIT, PDGFRB, RAF1, TNNI3K
MIDOSTAURINChEMBL + PubChemPhase 4 (approved)CDK19, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TNNI3K
NILOTINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, DDR2, FLT3, KIT, PDGFRB, RAF1, RET, TNNI3K
REBASTINIBChEMBLPhase 2BRAF, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, RAF1, RET
TOZASERTIBChEMBLPhase 2CDK19, DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
IdelalisibPubChemApprovedBRAF, DDR2, FGFR1, FLT3, FLT4, KIT, PDGFRB, RAF1, RET
NINTEDANIBChEMBLPhase 4 (approved)DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
TIVOZANIBChEMBLPhase 4 (approved)DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
CEDIRANIBChEMBLPhase 3DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
DOVITINIBChEMBLPhase 3DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
CEP-32496ChEMBLPhase 2BRAF, DDR2, FLT3, KDR, KIT, PDGFRB, RAF1, RET
ILORASERTIBChEMBLPhase 2CDK8, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
SU-014813ChEMBLPhase 2DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
BOSUTINIBChEMBL + PubChemPhase 4 (approved)CDK19, DDR2, FLT3, KIT, PDGFRB, RET, TNNI3K
CABOZANTINIBChEMBL + PubChemPhase 4 (approved)DDR2, FGFR1, FLT3, FLT4, KDR, KIT, RET
ENTRECTINIBChEMBL + PubChemPhase 4 (approved)DDR2, FGFR1, FLT3, FLT4, KDR, KIT, RET
INFIGRATINIBChEMBLPhase 4 (approved)BRAF, FGFR1, FLT3, FLT4, KDR, KIT, RET
LENVATINIBChEMBLPhase 4 (approved)DDR2, FGFR1, FLT4, KDR, KIT, PDGFRB, RET
SEMAXANIBChEMBLPhase 3FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
VATALANIBChEMBLPhase 3CDK19, CDK8, FLT4, KDR, KIT, PDGFRB, RET
CENISERTIBChEMBLPhase 2FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
DANUSERTIBChEMBLPhase 2DDR2, FGFR1, FLT3, FLT4, KDR, KIT, RET
DEFOSBARASERTIBChEMBLPhase 2DDR2, FLT3, FLT4, KDR, KIT, PDGFRB, RET
MILCICLIBChEMBLPhase 2DDR2, FGFR1, FLT3, FLT4, KIT, PDGFRB, RET
OSI-632ChEMBLPhase 2DDR2, FGFR1, FLT3, FLT4, KDR, PDGFRB, RET
TANDUTINIBChEMBLPhase 2DDR2, FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB
BinimetinibPubChemApprovedBRAF, DDR2, FGFR1, FLT3, KDR, PDGFRB, RET
FostamatinibChEMBL + PubChemPhase 4 (approved)BRAF, DDR2, FGFR1, FLT3, PDGFRB, RET
PEXIDARTINIBChEMBL + PubChemPhase 4 (approved)CDK19, DDR2, FLT3, KDR, KIT, PDGFRB
RUXOLITINIBChEMBL + PubChemPhase 4 (approved)BRAF, CDK19, DDR2, KIT, RET, TNNI3K
BRIGATINIBChEMBLPhase 4 (approved)FGFR1, FLT3, FLT4, KDR, KIT, RET
BRIVANIBChEMBLPhase 3FGFR1, FLT4, KDR, KIT, PDGFRB, RET
CANERTINIBChEMBLPhase 3FLT3, KDR, KIT, PDGFRB, RET, TNNI3K
SARACATINIBChEMBLPhase 3DDR2, FLT3, KDR, KIT, PDGFRB, RET
ENMD-2076ChEMBLPhase 2DDR2, FGFR1, FLT3, KDR, KIT, RET
LUCITANIBChEMBLPhase 2DDR2, FGFR1, FLT4, KDR, PDGFRB, RET
MK-2461ChEMBLPhase 2FGFR1, FLT3, FLT4, KDR, PDGFRB, RET
dacomitinibPubChemApprovedBRAF, DDR2, FGFR1, FLT3, PDGFRB, RET
TrametinibPubChemApprovedBRAF, DDR2, FGFR1, FLT3, PDGFRB, RET

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot